Aviance Capital Partners LLC lowered its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 0.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,564 shares of the company’s stock after selling 46 shares during the period. Aviance Capital Partners LLC’s holdings in Merck & were worth $998,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Capstone Asset Management Co. raised its stake in shares of Merck & by 1.7% in the 1st quarter. Capstone Asset Management Co. now owns 74,438 shares of the company’s stock worth $4,730,000 after buying an additional 1,260 shares in the last quarter. Adirondack Trust Co. grew its holdings in shares of Merck & by 0.4% in the 1st quarter. Adirondack Trust Co. now owns 11,334 shares of the company’s stock worth $720,000 after acquiring an additional 41 shares during the last quarter. Grassi Investment Management grew its holdings in shares of Merck & by 0.6% in the 1st quarter. Grassi Investment Management now owns 128,196 shares of the company’s stock worth $8,146,000 after acquiring an additional 752 shares during the last quarter. TNB Financial acquired a new position in shares of Merck & in the 1st quarter worth $3,462,000. Finally, Edge Wealth Management LLC grew its holdings in shares of Merck & by 0.7% in the 1st quarter. Edge Wealth Management LLC now owns 23,614 shares of the company’s stock worth $1,500,000 after acquiring an additional 175 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Merck & Company, Inc. (NYSE MRK) traded down 0.24% on Tuesday, reaching $65.83. The company’s stock had a trading volume of 2,535,821 shares. The company has a 50 day moving average price of $63.46 and a 200 day moving average price of $63.69. The company has a market cap of $179.54 billion, a P/E ratio of 35.64 and a beta of 0.81. Merck & Company, Inc. has a 52-week low of $58.29 and a 52-week high of $66.80.

Merck & (NYSE:MRK) last released its earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion during the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.93 EPS. On average, analysts anticipate that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.

COPYRIGHT VIOLATION WARNING: “Merck & Company, Inc. (MRK) Holdings Trimmed by Aviance Capital Partners LLC” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/19/merck-company-inc-mrk-holdings-trimmed-by-aviance-capital-partners-llc.html.

A number of brokerages recently issued reports on MRK. BMO Capital Markets restated a “buy” rating and issued a $72.00 target price on shares of Merck & in a report on Friday, September 8th. Credit Suisse Group restated an “outperform” rating and issued a $74.00 target price (down from $75.00) on shares of Merck & in a report on Tuesday, September 5th. Cowen and Company restated a “hold” rating and issued a $70.00 target price on shares of Merck & in a report on Friday, September 1st. Jefferies Group LLC restated a “sell” rating and issued a $52.00 target price on shares of Merck & in a report on Sunday, August 20th. Finally, HSBC Holdings plc upgraded Merck & from a “reduce” rating to a “hold” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $70.00.

Merck & Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.